Tocotrienols for Health & Longevity - Quick Reference Sheet
evipedia.aidev
← Back

Tocotrienols for Health & Longevity

Created on 08/12/2026 – Quick Reference based on Evidence Review created using AI4L / Grok 4 – Audit

Tocotrienols are less common vitamin E forms with human evidence for modest blood-sugar improvement in type 2 diabetes, better fatty-liver markers, and small rises in protective high-density lipoprotein cholesterol. About 100–600 mg per day looks generally well tolerated. Main caution is extra bleeding risk with blood-thinning medicines. (Full Review)

Protocol

Dose
100–200 mg/day
Longevity/metabolic range; clinical NAFLD/diabetes trials use 250–600 mg/day
Timing
Twice daily with fat meals
Short half-life (~2–4.5 h); not on an empty stomach
Formulation
Annatto δ/γ or palm TRF
δ-rich annatto for metabolic use; α-containing TRF for neuro focus; limit high α-tocopherol
Time to effect
Glycemic control
≥8–12 weeks
HbA1c needs ≥8–12 weeks to move
Fatty liver markers
12–24 weeks
Ultrasound/enzyme changes in NAFLD trials
Lipids & inflammation
4–12 weeks
HDL, triglycerides, and inflammatory marker shifts

Benefits

Contraindications
  • Active pathological bleeding, known bleeding disorders, or recent major hemorrhage (until cleared)
  • Therapeutic anticoagulation that cannot be monitored (relative avoidance without clinician oversight)
  • Pregnancy or lactation at high supplemental doses (insufficient safety data)
  • Known allergy to palm, rice bran, or annatto source materials
  • Children outside research settings
    •
Key Interactions
  • Anticoagulants (warfarin, apixaban, rivaroxaban, dabigatran)
  • Antiplatelet agents (aspirin, clopidogrel, ticagrelor)
  • High-dose α-tocopherol supplements
  • Bile-acid sequestrants (cholestyramine, colesevelam)
  • Orlistat and other fat-blocker agents
  • High-dose omega-3, garlic, or ginkgo (with anticoagulants)
    •

Risk & Side Effects

  • High:
  • Medium: Additive bleeding risk with anticoagulants / antiplatelets
    •
  • Low: Gastrointestinal discomfort; competition with / displacement of tocopherols; liver enzyme fluctuations
    •
  • Speculative: High-dose vitamin E outcome concerns extrapolated from α-tocopherol
    •

Monitoring

Marker Target Why
HbA1c ~5.0–5.4% (personalize) Tracks glycemic response
Fasting glucose ~75–90 mg/dL Short-term glycemic control
ALT Low-normal for lab (often <25–30 U/L) Liver injury / NAFLD signal
AST Low-normal for lab Liver / tissue enzyme
HDL-C Higher within personal context (e.g., >50–60 mg/dL) Lipid benefit signal
Triglycerides <100 mg/dL functional target Metabolic / TG response
hs-CRP <1.0 mg/L Systemic inflammation
INR (if on warfarin) Per anticoagulation clinic target Bleeding risk

Cadence: Baseline before start; recheck core labs at about 8–12 weeks after a stable dose, then every 3–6 months during long-term use

Qualitative Assessment

  • Energy and recovery: afternoon fatigue and post-exercise recovery over 4–8 weeks
  • Bleeding/bruising: unusual bruising, gum bleeding, or prolonged cuts as stop-and-review signals
  • GI tolerance: soft stools or nausea after dose increases (often better with food or split dosing)
  • Cognitive clarity (exploratory): subjective only; no validated consumer biomarker yet
Not medical advice. Educational distillation of a single evidence review. Confirm any decision with a qualified clinician, especially in the presence of prescription drugs or chronic conditions.